Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194960 · ClinicalTrials.gov registry record · Phase 2
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
A Phase 2 study, sponsored by Oxford BioMedica.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01194960 is a Phase 2 study that was terminated before completion, run by Oxford BioMedica. The registered enrollment target is 25 participants.
The verdict
NCT01194960, a Phase 2 study, was terminated before completion, sponsored by Oxford BioMedica.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression free survival (PFS) of subjects with HRPC.
Interventions
- DRUG Docetaxel
- DRUG TroVax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194960
The ClinicalTrials.gov registry entry for NCT01194960 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oxford BioMedica, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01194960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194960 about?
NCT01194960 is a clinical study titled "TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)". Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination ther...
What is the current status of trial NCT01194960?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2010-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01194960?
The interventions under investigation include: Docetaxel (DRUG), TroVax (DRUG).
Who is sponsoring clinical trial NCT01194960?
This trial is sponsored by Oxford BioMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.